Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00394693 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma
A Phase 2 study, sponsored by Transgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00394693 is a Phase 2 study that has completed, run by Transgene. The registered enrollment target is 13 participants.
The verdict
NCT00394693, a Phase 2 study, has completed, sponsored by Transgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of a four-month dosing period of intra-lesional injection of TG1042 in patients with relapsing CBCL. Patients will receive intra-tumoral injections of an adenoviral vector construct containing the human interferon gamma gene (TG1042), in an attempt to enhance immune responses with anti-tumor activity. This local administration induces tumour cell killing at the injected tumour sites.
Interventions
- GENETIC Adenovirus Interferon gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00394693
The ClinicalTrials.gov registry entry for NCT00394693 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Transgene, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adenovirus Interferon gamma is the first listed.
NCT00394693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00394693 about?
NCT00394693 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma". The primary objective of this study is to evaluate the efficacy of a four-month dosing period of intra-lesional injection of TG1042 in patients with relapsing CBCL. Patients will receive intra-tumoral injections of an adenoviral vector construct containing the human interferon gamma gene (TG1042), ...
What is the current status of trial NCT00394693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00394693?
The interventions under investigation include: Adenovirus Interferon gamma (GENETIC).
Who is sponsoring clinical trial NCT00394693?
This trial is sponsored by Transgene, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.